Summary

The Glioblastoma Multiforme Treatment (GBM) market is expected to grow at a strong CAGR of around 8% during the forecast period. The market for glioblastoma multiforme treatment market is witnessing growth mainly due to the development of new and innovative therapies to improve patient outcomes. Techniques such as the genetic mutation in the specific tumor cells are gaining popularity in the treatment of glioblastoma multiforme which is attributed to the growth of the market. For example, some tumors have mutations in the epidermal growth factor receptor (EGFR) gene, which can be targeted with drugs such as gefitinib and erlotinib. Further, increasing approvals of drugs for the treatment of glioblastoma multiforme is also a responsible factor for market growth of the glioblastoma treatment market. For instance, in June 2022, the FDA approved the two-drug combination dabrafenib and trametinib. These agents fall into the category of targeted therapies that attack cancer cells harboring BRAF mutations.

Some of the major players operating in the market include Merck & Co., Inc.; Amgen Inc.; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Amneal Pharmaceuticals LLC; Karyopharm; Sumitomo Pharma Oncology, Inc; and Bristol-Myers Squibb Company Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst treatment, the chemotherapy segment is expected to grow with the highest CAGR during the forecast period.”
Based on treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (TTF) therapy, and immunotherapy. The chemotherapy segment is expected to grow with the highest CAGR during the forecast period. Chemotherapy involves the use of drugs to destroy cancer cells, and it is often used in combination with other treatments such as surgery and radiation therapy to improve the chances of success. The increasing incidence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced chemotherapy drugs and delivery technologies are responsible for the growth of the segment.

“Amongst end-use, the direct sales segment held a dominant share in 2021”
Based on the end-use, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held a dominant share in 2021. The growth of the segment is driven by factors such as the increasing incidence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced diagnostic and treatment technologies. Further, hospitals have world-class facilities and a wealth of expertise in treating GBM and other types of cancer, and they work closely with academic institutions and research organizations to develop new treatments and improve patient outcomes.

“Asia Pacific is expected to grow with the highest CAGR Glioblastoma Multiforme Treatment (GBM) market during the forecast period.”
The Asia Pacific is expected to grow with the highest CAGR glioblastoma multiforme treatment (GBM) market during the forecast period. This is mainly due to the presence of large and rapidly aging populations, and increasing incidence of brain tumors, including GBM. For instance, as per the Asian Development Bank, by 2050, one in four people in the Asia-Pacific region will be over the age of 60. The region's elderly (over 60) population will triple between 2010 and 2050, reaching nearly 1.3 billion.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global Glioblastoma Multiforme Treatment (GBM) market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents